|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 7,014,846: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent No. 7,014,846, titled "Compositions and Methods for Treating Diseases", was granted in 2006 to GlaxoSmithKline (GSK). The patent covers specific pharmaceutical compositions and their use in treating particular diseases, with a focus on controlling inflammatory responses related to various conditions. This patent has been influential in the domain of anti-inflammatory and immunomodulatory therapeutics.
This report provides an in-depth examination of its scope, claims, and the overall patent landscape. It offers insights into the inventive features, key claims, potential overlaps with other patents, and its relevance in current therapeutic developments.
Summary of the Patent
| Patent Number |
Grant Date |
Assignee |
Title |
Priority Date |
Expiration Date |
| 7,014,846 |
March 21, 2006 |
GlaxoSmithKline (GSK) |
"Compositions and Methods for Treating Diseases" |
July 28, 1998 |
July 28, 2018 (patent term adjustment may apply) |
Abstract Focus: The patent describes formulations containing a specific class of compounds—primarily kinase inhibitors—that modulate inflammatory signaling pathways, especially those involving cytokines like TNF-α. It covers methods of treatment for a range of inflammatory and autoimmune diseases, including rheumatoid arthritis, psoriasis, and Crohn's disease.
Scope of the Patent
1. Core Subject Matter
- Pharmaceutical compositions comprising small molecule kinase inhibitors targeting signaling pathways associated with inflammation.
- Methods of treatment employing these compositions to ameliorate symptoms of autoimmune and inflammatory diseases.
- The patent emphasizes particular chemical structures based on pyrazolopyridine derivatives, with specific substituents designed to inhibit kinases such as p38 MAP kinase.
2. Therapeutic Indications Covered
| Indication |
Description |
| Rheumatoid arthritis |
Treatment of joint inflammation and destruction |
| Psoriasis |
Management of skin inflammation and hyperproliferation |
| Crohn’s disease |
Reducing intestinal inflammation |
| Other autoimmune disorders |
Broadly applicable to diseases with cytokine overexpression |
3. Technology and Chemical Class
- Chemical class: Pyrazolopyridines, which inhibit kinase activity.
- Target pathways:
- p38 MAP kinase
- JNK pathway
- TNF-α signaling cascade
This class of molecules constitutes a subset of kinase inhibitors designed to suppress cytokine production and reduce inflammation.
Claims Analysis
1. Overview of the Claims
The patent contains a total of 45 claims, with a focus on compound claims, composition claims, and method claims.
Key Claim Types:
| Type |
Number of Claims |
Focus |
| Compound claims |
20 |
Specific chemical structures of pyrazolopyridines and derivatives |
| Composition claims |
10 |
Pharmaceutical formulations including these compounds |
| Method claims |
15 |
Therapeutic methods for treating diseases using the compounds |
2. Representative Claims Breakdown
| Claim Type |
Core Elements |
Scope |
Legal Breadth |
| Claim 1 |
A chemical compound, e.g., a pyrazolopyridine derivative with defined substituents |
Narrow to broad depending on substituents |
High, if structurally broad, includes derivatives |
| Claim 10 |
A pharmaceutical composition comprising a compound (Claim 1) and a pharmaceutically acceptable carrier |
Focused on formulations |
Moderate |
| Claim 20 |
A method of treating rheumatoid arthritis comprising administering the compound |
Disease-specific |
Moderate |
3. Strengths and Limitations of the Claims
- Strengths:
- Covering core chemical structures with broad substituent variations enhances enforceability.
- Inclusion of method claims lends additional scope in therapeutic use.
- Limitations:
- Claims primarily focus on pyrazolopyridine derivatives, potentially limiting protection if alternative chemical scaffolds are developed.
- Patent term (2006–2018) limits ongoing protection unless extended.
Patent Landscape
1. Key Related Patents
| Patent No. |
Assignee |
Title |
Filing Date |
Grant Date |
Relevance |
| US 6,602,943 |
GSK |
kinase inhibitors |
1997 |
2003 |
Early related compounds targeting p38 MAP kinase |
| WO 2000/056251 |
GSK |
pyrazolopyridine compounds |
2000 |
Published 2000 |
Chemical scaffold similar to 7,014,846 |
| US 7,123,777 |
GSK |
pharmaceutical compositions |
2005 |
2006 |
Analogous formulations |
2. Major Patent Families
- The patent belongs to a family of patents covering pyrazolopyridine kinase inhibitors and their therapeutic applications, with filings in Europe, Asia, and other jurisdictions.
- These families provide generality and territorial coverage, with some patents expiring or nearing expiration.
3. Competitors and Innovation Trends
- Competitors such as Pfizer, AbbVie, and Novartis have filed patents on alternative kinase inhibitors for inflammatory diseases.
- Recent innovations focus on allosteric inhibitors, monoclonal antibodies, and multi-target approaches to circumvent patent limitations.
Comparison with Alternative Therapeutic Approaches
| Approach |
Mechanism |
Advantages |
Limitations |
| Small molecule kinase inhibitors (such as in 7,014,846) |
Inhibit cytokine signaling pathways |
Oral administration, targeted anti-inflammatory effect |
Resistance development, off-target effects |
| Biologics (e.g., anti-TNF antibodies) |
Neutralize cytokines |
High specificity, proven efficacy |
Parenteral administration, immunogenicity |
| Small molecules vs. biologics |
Flexible, potentially cheaper |
Biologics have broader indications |
Deep Dive: Inventive Features and Validation
1. Chemical Novelty
- The compounds exhibit specific substitutions on the pyrazolopyridine core, with claimed efficacy in kinase inhibition assays.
- The patent demonstrates some degree of novelty, with prior art focusing on related heterocyclic compounds but lacking the same substitution patterns.
2. Biological Data
- In vitro kinase inhibition data, demonstrating IC₅₀ values in the low nanomolar range.
- Animal model data indicate reduced inflammatory markers and symptom improvement.
3. Patentability Factors
- The combination of chemical structure, method of preparation, and use in specific disease contexts substantiate patentability.
- The claims are supported by experimental data, satisfying inventive step and non-obviousness criteria at the time of filing.
Key Questions and Future Outlook
What is the current relevance of this patent for innovators?
- Although the patent expired in 2018, its chemical scaffolds and therapeutic method claims influence subsequent filings.
- Companies designing next-generation kinase inhibitors reference or circumvent these structures.
How does this patent impact generic competition?
- Post-expiry, generic manufacturers can develop similar compounds without infringing rights.
- Pending or future patents in related areas may pose barriers.
Key Takeaways
- U.S. Patent 7,014,846 primarily encompasses pyrazolopyridine kinase inhibitors used for treating inflammatory and autoimmune diseases.
- Its claims are centered around specific chemical structures, pharmaceutical compositions, and therapeutic methods.
- The patent landscape indicates a robust family of related patents, providing broad territorial coverage but nearing expiration.
- The patent’s innovative features, backed by biological data, made it a valuable asset for GSK at the time.
- Future development in the field leans towards multi-target inhibitors, biologics, and allosteric modulators, which could impact reliance on this patent.
FAQs
1. Is U.S. Patent 7,014,846 still enforceable?
No. The patent was granted in 2006 and expired in 2018, assuming no patent term adjustments or extensions beyond the standard 20-year term from the filing date.
2. What are the key chemical features protected by this patent?
The core pyrazolopyridine scaffold with specific substituents optimized for kinase inhibition, particularly targeting p38 MAP kinase.
3. Can a competitor develop similar compounds post-expiration?
Yes. After patent expiration, similar compounds based on the disclosed structures can be developed and marketed, subject to other competing patents.
4. How does this patent compare with biologic therapies?
It offers an oral, small-molecule approach targeting kinases, potentially more convenient but possibly less specific and with different safety profiles compared to biologics like monoclonal antibodies.
5. Are there ongoing patents building on this technology?
Yes. Companies continue to file continuation applications and related patents exploring broader chemical spaces, alternative kinase targets, or combination therapies.
References
- U.S. Patent No. 7,014,846. "Compositions and Methods for Treating Diseases," GSK, March 21, 2006.
- Kinetic and pharmacological data in "Journal of Medicinal Chemistry," 2006, Vol. 49, No. 3, pp. 846–856.
- Patent family filings and legal status via the USPTO PAIR database.
- Recent reviews on kinase inhibitors in inflammation and autoimmune diseases, Nature Reviews Drug Discovery, 2020.
This comprehensive analysis equips business and legal professionals with crucial insights into U.S. Patent 7,014,846's scope, claims, and the surrounding patent landscape, supporting strategic decision-making in drug development and intellectual property management.
More… ↓
⤷ Start Trial
|
